Is this Korea’s biotech moment? A BioCentury podcast

BioCentury heads to Cambridge for a deep dive on South Korea’s biotech ecosystem

Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of the BioCentury This Week podcast recorded at Venture Café Cambridge, BioCentury’s Simone Fishburn and Josh Berlin are joined by a quartet of investors and executives with deep knowledge of Korea’s life sciences ecosystem to discuss Korea biotech’s push to globalize and the opportunities in the country for Western companies. The discussion comes as Korea’s government pushes to make life sciences a long-term pillar of growth and domestic companies are displaying more breadth than ever in terms of indications and technologies.

The four guests joining BioCentury were Aram Hong, CEO of Korean start-up Apollon; Spencer Nam, managing partner of KSV Global; Debra Peattie, managing partner, SV Investment US; and Andy Whittle, global head of cardiorenal-metabolic BD&L at Boehringer Ingelheim GmbH.

The podcast was recorded Nov. 6 on stage at the Venture Café Cambridge during the K-Blockbuster Night hosted by KHIDI, the Korea Health Industry Development Institute. BioCentury analyses discussed during the podcast include one on Asian deals and another on the speed of clinical trials in China.

BioCentury returns to Asia early next year for the 5th East-West Summit, March 9-11 in Seoul. Register today as a delegate or apply to join the Presenting Company Class to take advantage of early bird rates.